CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data

Abstract Breast cancer patients with residual disease after neoadjuvant chemotherapy and surgery may benefit from additional anti-cancer therapies. Capecitabine, an oral antimetabolite and prodrug of 5-Flurouracil, has been approved for treating metastatic breast cancer. One randomized clinical tria...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jo Anne Zujewski, Lawrence Rubinstein
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e9264fc7d1f847c1825dcf1a2d935aed
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9264fc7d1f847c1825dcf1a2d935aed
record_format	dspace
spelling	oai:doaj.org-article:e9264fc7d1f847c1825dcf1a2d935aed2021-12-02T15:18:23ZCREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data10.1038/s41523-017-0029-32374-4677https://doaj.org/article/e9264fc7d1f847c1825dcf1a2d935aed2017-07-01T00:00:00Zhttps://doi.org/10.1038/s41523-017-0029-3https://doaj.org/toc/2374-4677Abstract Breast cancer patients with residual disease after neoadjuvant chemotherapy and surgery may benefit from additional anti-cancer therapies. Capecitabine, an oral antimetabolite and prodrug of 5-Flurouracil, has been approved for treating metastatic breast cancer. One randomized clinical trial (CREATE-X) of capecitabine versus no additional therapy has been conducted in women with early stage breast cancer who received standard chemotherapy pre-operative therapy and had residual invasive breast cancer at the time of surgery. Results from CREATE-X, showed that capecitabine had a statistically significant survival advantage compared with no additional therapy. This perspective provides a review and analysis of the available data from CREATEx in the context of results from other adjuvant trials of capecitabine in early stage breast cancer that had disease–free survival as a primary endpoint. We conclude that although the previously published studies of capecitabine in the adjuvant setting did not meet their primary endpoint, the data from these studies are consistent with the hypothesis that capecitabine may offer additional survival benefit in patients with chemo-refractory breast cancer at the time of surgery after receiving standard chemotherapy. In these patients, offering a course of adjuvant capecitabine or enrolling the patient in a clinical trial are appropriate therapeutic options. The patient should be informed about both the increased survival observed in the CREATEx trial and the expected toxicities from capecitabine chemotherapy.Jo Anne ZujewskiLawrence RubinsteinNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Breast Cancer, Vol 3, Iss 1, Pp 1-5 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jo Anne Zujewski Lawrence Rubinstein CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data
description	Abstract Breast cancer patients with residual disease after neoadjuvant chemotherapy and surgery may benefit from additional anti-cancer therapies. Capecitabine, an oral antimetabolite and prodrug of 5-Flurouracil, has been approved for treating metastatic breast cancer. One randomized clinical trial (CREATE-X) of capecitabine versus no additional therapy has been conducted in women with early stage breast cancer who received standard chemotherapy pre-operative therapy and had residual invasive breast cancer at the time of surgery. Results from CREATE-X, showed that capecitabine had a statistically significant survival advantage compared with no additional therapy. This perspective provides a review and analysis of the available data from CREATEx in the context of results from other adjuvant trials of capecitabine in early stage breast cancer that had disease–free survival as a primary endpoint. We conclude that although the previously published studies of capecitabine in the adjuvant setting did not meet their primary endpoint, the data from these studies are consistent with the hypothesis that capecitabine may offer additional survival benefit in patients with chemo-refractory breast cancer at the time of surgery after receiving standard chemotherapy. In these patients, offering a course of adjuvant capecitabine or enrolling the patient in a clinical trial are appropriate therapeutic options. The patient should be informed about both the increased survival observed in the CREATEx trial and the expected toxicities from capecitabine chemotherapy.
format	article
author	Jo Anne Zujewski Lawrence Rubinstein
author_facet	Jo Anne Zujewski Lawrence Rubinstein
author_sort	Jo Anne Zujewski
title	CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data
title_short	CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data
title_full	CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data
title_fullStr	CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data
title_full_unstemmed	CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data
title_sort	create-x a role for capecitabine in early-stage breast cancer: an analysis of available data
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/e9264fc7d1f847c1825dcf1a2d935aed
work_keys_str_mv	AT joannezujewski createxaroleforcapecitabineinearlystagebreastcancerananalysisofavailabledata AT lawrencerubinstein createxaroleforcapecitabineinearlystagebreastcancerananalysisofavailabledata
_version_	1718387482318340096

CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data

Ejemplares similares